z-logo
Premium
Oral Presentations
Author(s) -
Borbath, Ivan,
The Liver meeting
Publication year - 2012
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.26033
Subject(s) - citation , world wide web , medicine , computer science , library science
Background: Tivantinib (T), a selective, oral inhibitor of MET, the hepatocyte growth factor (HGF) receptor, was successfully tested in HCC patients (pts) in Phase 1 studies as monotherapy and with sorafenib. Methods: Multi center RCT; key selection criteria: unresectable HCC, 1 prior systemic therapy, PS <2; no Child-Pugh B-C. Randomization: 2:1 to T or placebo (P); dose: 360 mg bid (TA; after 57 patients were treated, dose was reduced to 240 mg bid (TB) in all patients due to G≥3 neutropenia rate); stratification: PS, vascular invasion (VI). Tumor evaluation: by CT / MRI every 6 weeks; central radiology review by RECIST 1.1. Crossover to open label T was allowed after PD. Endpoints included: time to tumor progression (TTP) in the intent-to-treat (ITT) population; disease control rate (DCR), progression free survival (PFS), overall survival (OS), efficacy in MET Diagnostic High (MET >2+ in >50% of tumor cells by immunohistochemistry) patients, safety. Results: 107 enrolled patients, 71 on T (TA: 38, TB: 33), 36 on P. Pt characteristics were generally well balanced, also when grouped by MET status. In ITT, median TTP was: 1.6 vs 1.4 mos (HR 0.64, 90%CI 0.43-0.94; P=0.04). Most promising results were obtained in the MET High group, TTP: 2.7 vs 1.4 mos (HR 0.43, 95%CI 0.19-0.97; P=0.03), DCR (95%CI): 50% (28–72%) vs 20% (4–48%), OS 7.2 vs 3.8 mos (HR 0.38, 95%CI 0.18-0.81, P=0.01). Prognostic role of several factors was evaluated in the P group: MET High patients had a 60% higher risk of progression and a 195% higher risk of death; high HGF (cutoff: median value of 2307 pg/mL) patients showed a similar trend in terms of TTP and OS. In MET High patients on T, the most common AEs were fatigue (7, 31.7%) and asthenia (6, 27.3%). Blood levels (PK) of T were higher than in non HCC studies. No relation between MET and HBV/HCV, HGF or PK was observed. Strict dose reduction guidelines and the TB starting dose dramatically reduced the G≥3 neutropenia rate without changing efficacy. Conclusions: This study showed MET positivity is an independent, strong, negative prognostic factor in pretreated HCC patients. MET High patients on tivantinib achieved a 163% survival improvement compared to placebo. Biopsy is key to establish the MET status. Larger studies with tivantinib are being planned in MET High HCC patients

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here